Lack of antibodies to LAV/HTLV-III in hepatitis B vaccine recipients. NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Lack of antibodies to LAV/HTLV-III in hepatitis B vaccine recipients.

Eur J Epidemiol. 1985 Dec;1(4):323-5. Unique Identifier : AIDSLINE MED/87030796
Papaevangelou G; Roumeliotou-Karayannis A; Kallinikos G; Politou K

Abstract: There is no evidence up to now that the currently available plasma hepatitis B vaccine transmits the agent of AIDS. To support further the safety of this vaccine we examined 137 vaccinees for the presence of antibodies to LAV/HTLV-III. Three groups had received Merck, Sharp and Dohme hepatitis B vaccine (two groups of 25 Air Force cadets vaccinated with investigational lots and 18 multiply transfused children vaccinated with a commercial lot); another two groups (50 Air Force cadets and 19 multiply transfused) were vaccinated with two commercial lots of Institut Pasteur vaccine. Sera were collected before inoculation, 7 and 24 months later. Enzyme linked immunosorbent assay was used for the detection of antibodies to LAV/HTLV-III. Positive sera were tested again by Western Blot and Radioimmune Precipitation Assay to exclude non-specific binding. Antibodies to LAV/HTLV-III were not detected in any of the sera examined, providing evidence for safety. We believe that these data increase the acceptance of hepatitis B vaccine.
Keywords: Acquired Immunodeficiency Syndrome/*TRANSMISSION Antibodies, Viral/*ANALYSIS Greece Hepatitis B/*PREVENTION & CONTROL Human HIV/*IMMUNOLOGY Risk Support, Non-U.S. Gov't Viral Hepatitis Vaccines/*STANDARDS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDtransmissionantibodies,viral/KWDanalysisgreecehepatitisb/KWDprevention&controlhumanhiv/KWDimmunologyrisksupport,non-uKWDsKWDgov'tviralhepatitisvaccines/KWDstandardsjournalarticle
870228
M8720247

Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .